Cliff Asness's AKBA Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 646,679 shares of Akebia Therapeutics, Inc. (AKBA) worth $1.04 M, representing 0.00% of the portfolio. First purchased in 2017-Q3, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in AKBA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 677,703 shares. Largest reduction occurred in Q3 2022, reducing 862,168 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Akebia Therapeutics (AKBA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Akebia Therapeutics (AKBA) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +204,207 | Add 46.15% | 646,679 | $1.61 |
| Q3 2025 | +16,523 | Add 3.88% | 442,472 | $2.73 |
| Q2 2025 | +248,988 | Add 140.70% | 425,949 | $3.64 |
| Q1 2025 | +20,499 | Add 13.10% | 176,961 | $1.92 |
| Q4 2024 | +15,413 | Add 10.93% | 156,462 | $1.90 |
| Q3 2024 | +141,049 | New Buy | 141,049 | $1.32 |
| Q3 2022 | -862,168 | Sold Out | 0 | $0.00 |
| Q2 2022 | +677,703 | Add 367.39% | 862,168 | $0.35 |
| Q1 2022 | +102,691 | Add 125.58% | 184,465 | $0.72 |
| Q4 2021 | +9,004 | Add 12.37% | 81,774 | $2.26 |
| Q3 2021 | +58,751 | Add 419.08% | 72,770 | $2.89 |
| Q2 2021 | -25,229 | Reduce 64.28% | 14,019 | $3.78 |
| Q1 2021 | -160,845 | Reduce 80.39% | 39,248 | $3.39 |
| Q4 2020 | -167,193 | Reduce 45.52% | 200,093 | $2.80 |
| Q3 2020 | +138,227 | Add 60.35% | 367,286 | $2.51 |
| Q2 2020 | +11,936 | Add 5.50% | 229,059 | $13.58 |
| Q1 2020 | -80,356 | Reduce 27.01% | 217,123 | $7.58 |
| Q4 2019 | +207,708 | Add 231.38% | 297,479 | $6.32 |
| Q3 2019 | +78,575 | Add 701.81% | 89,771 | $3.92 |
| Q2 2019 | +11,196 | New Buy | 11,196 | $4.82 |
| Q2 2018 | -22,622 | Sold Out | 0 | $0.00 |
| Q1 2018 | -17,209 | Reduce 43.21% | 22,622 | $9.55 |
| Q4 2017 | -11,785 | Reduce 22.83% | 39,831 | $14.86 |
| Q3 2017 | +51,616 | New Buy | 51,616 | $19.66 |
Cliff Asness's Akebia Therapeutics Investment FAQs
Cliff Asness first purchased Akebia Therapeutics, Inc. (AKBA) in Q3 2017, acquiring 51,616 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Akebia Therapeutics, Inc. (AKBA) for 24 quarters since Q3 2017.
Cliff Asness's largest addition to Akebia Therapeutics, Inc. (AKBA) was in Q2 2022, adding 862,168 shares worth $304,000.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 646,679 shares of Akebia Therapeutics, Inc. (AKBA), valued at approximately $1.04 M.
As of the Q4 2025 filing, Akebia Therapeutics, Inc. (AKBA) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Akebia Therapeutics, Inc. (AKBA) was 862,168 shares, as reported at the end of Q2 2022.